The safety of post-exposure vaccination of mice infected with Mycobacterium tuberculosis

Vaccine

Volumn 26, Issue 48, 2008, Pages 6092-6098

  Derrick, Steven C ^a   Perera, L P ^b   Dheenadhayalan, Veerabadran ^c   Yang, Amy ^a   Kolibab, Kristopher ^a   Morris, Sheldon L ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c Aeras Global TB Vaccine Foundation   (United States)

Author keywords

Safety; Tuberculosis; Vaccine

Indexed keywords

BACTERIAL DNA; BCG VACCINE; DNA VACCINE; DNA VACCINE HPS65; POST EXPOSURE TUBERCULOSIS VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; BCG VACCINATION; CONTROLLED STUDY; DISEASE MODEL; DRUG SAFETY; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; VACCINATION;

ANIMALS; BACTERIAL PROTEINS; BCG VACCINE; CHAPERONINS; COLONY COUNT, MICROBIAL; GENETIC VECTORS; LUNG; MICE; MICE, INBRED C57BL; MYCOBACTERIUM TUBERCULOSIS; SURVIVAL ANALYSIS; TUBERCULOSIS VACCINES; TUBERCULOSIS, PULMONARY; VACCINES, DNA;

EID: 55249111975     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.09.011     Document Type: Article

References (29)

1. World Health Organization. Global tuberculosis control-surveillance, planning, financing; 2007. http://www.who.int/tb/publications/global_report/en/.
2. World Health Organization. Fact sheet No. 104; 2002. http://www.who.int/mediacentre/facsheets.
3. Locht C., Rouanet C., Hougardy J.M., and Mascart F. How a different look at latency can help develop novel diagnostics and vaccines against tuberculosis. Expert Opin Biol Ther 7 (2007) 1665-1677
4. Colditz G.A., Brewer T.F., Berkey C.S., Wilson M.E., Burdick E., Fineberg H.V., et al. Efficacy of BCG vaccine in the prevention of tuberculosis Meta-analysis of the published literature. JAMA 271 (1994) 698-702
5. Doherty T.M., Dietrich J., and Billeskov R. Tuberculosis subunit vaccines: from basic science to clinical testing. Expert Opin Biol Ther 7 (2007) 1539-1549
6. Gupta U.D., Katoch V.M., and McMurray D.M. Current status of TB vaccines. Vaccine 25 (2007) 3742-3751
7. Isemen M.D. A physicians guide to tuberculosis (2000), Lippencott, Williams and Wilkins, Philadelphia
8. Moreira A.L., Tsenova L., Aman M.H., Bekker L.G., Freeman S., Mangaliso B., et al. Mycobacterial antigens exacerbate disease manifestations in Mycobacterium tuberculosis-infected mice. Infect Immun 70 (2002) 2100-2107
9. Taylor J.L., Turner O.C., Basaraba R.J., Belisle J.T., Huygen K., and Orme I.M. Pulmonary necrosis resulting from DNA vaccination against tuberculosis. Infect Immun 71 (2003) 2192-2198
10. Basaraba R.J., Izzo A.A., Brandt L., and Orme I.M. Decreased survival of guinea pigs infected with Mycobacterium tuberculosis after multiple BCG vaccinations. Vaccine 24 (2006) 280-286
11. Rich A.R. The pathogenesis of tuberculosis (1951), Charles C. Thomas, Springfield
12. Egmose T. The effect of BCG vaccination in naturally infected tuberculin-positive individuals. Scand J Resp Dis 49 (1968) 123-146
13. Narain R., and Vallishayee R.S. BCG vaccination of tuberculosis patients and of strong reactors to tuberculin. Bull Int Union Tuberc 51 (1976) 243-246
14. Cunha A.J., Sant'Anna C.C., Mannarino R., Labanca T.C., Ferreira S., and March M.F. Adverse effects of BCG revaccination: a report on 13 cases from Rio de Janeiro, Brazil. Int J Tuberc Lung Dis 6 (2002) 1110-1113
15. Morris S., Kelley C., Howard A., Li Z., and Collins F.M. The immunogenicity of single and combination DNA vaccines. Vaccine 18 (2001) 2155-2163
16. Delogu G., Li A., Repique C., Collins F., and Morris S.L. DNA vaccine combinations expressing either tissue plasminogen activator signal sequence fusion proteins or ubiquitin-conjugated antigens induce sustained protective immunity in a mouse model of pulmonary tuberculosis. Infect Immun 70 (2002) 292-302
17. McCune R.M., Feldmann F.M., Lamber P.H., and McDermott W. Microbial persistence: the capacity of tubercle bacilli to survive sterilization in mouse tissues. J Exp Med 123 (1966) 445-468
18. Langermans J.A., Dohetry T.M., Vervenne R.A., van der Laan T., Lyashchenko K., Greenwald R., et al. Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6. Vaccine 23 (2005) 2740-2750
19. Derrick S.C., Yang A., and Morris S.L. A polyvalent DNA vaccine expressing an ESAT6-Ag85B fusion protein protects mice against a primary infection with Mycobacterium tuberculosis and boosts BCG-induced protective immunity. Vaccine 23 (2004) 780-788
20. Turner J., Rhoades E.R., Keen M., Belisle J.T., Frank A.A., and Orme I.M. Effective preexposure tuberculosis vaccines fail to protect when they are given in an immunotherapeutic mode. Infect Immun 68 (2000) 1706-1709
21. Collins F.M. Mycobacterial pathogenesis: a historical perspective. Front Biosci 3 (1998) e123-e132
22. Reece S.T., Stride N., Ovendale P., Reed S.G., and Campos-Neto A. Skin test performed with highly purified Mycobacterium tuberculosis recombinant protein triggers tuberculin shock in infected guinea pigs. Infect Immun 73 (2005) 3301-3306
23. Orme I. Safety issues regarding new vaccines against tuberculosis, with an emphasis on post-exposure vaccination. Tuberculosis 86 (2006) 68-73
24. Huygen K. DNA vaccination against mycobacterial diseases. Future Microbiol 1 (2006) 63-73
25. Roy E., Lowrie D.B., and Jolles Sr. Current strategies in TB immunotherapy. Curr Mol Med 7 (2007) 373-386
26. Lowrie D.B., Tascon R.E., Bonato V.L., Lima V.M., Faccioli L.H., Stavropoulos E., et al. Therapy of tuberculosis in mice by DNA vaccination. Nature 400 (1999) 269-271
27. Zhu D., Jiang S., and Luo X. Therapeutic effect of Ag85B and MPT64 DNA vaccines in a murine model of Mycobacterium tuberculosis infection. Vaccine 23 (2005) 4619-4624
28. Repique C.J., Li A., Collins F.M., and Morris S.L. DNA immunization in a mouse model of latent tuberculosis: effect of DNA vaccination on reactivation of disease and on reinfection with a secondary challenge. Infect Immun 70 (2002) 3318-3323
29. Pathan A.A., Sander C.R., Fletcher H.A., Poulton I., Alder N.C., Beveridge N.E., et al. Boosting BCG with recombinant modified vaccinia Ankara expressing antigen 85A: Different boosting intervals and implications for efficacy trials. PLOS One 2 (2007) e1052